All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub spoke to Philippe Moreau, CHU de Nantes, Nantes, FR. We asked, Is dara + VTd the best induction treatment for high-risk patients with newly diagnosed MM?
Is dara + VTd the best induction treatment for high-risk patients with newly diagnosed MM?
Philippe Moreau talks about the use of daratumumab (dara) plus the bortezomib, thalidomide, and dexamethasone (VTd) combination as induction therapy prior to stem cell transplantation. He discusses the findings of the CASSIOPEIA study.
CASSIOPET study: Is PET-CT a surrogate prognostic marker in transplant eligible patients with NDMM?
Philippe Moreau discusses the phase III, randomized CASSIOPET study, that looked at the effect of daratumumab in the context of stem cell...
How to achieve the best results in patients with high-risk MM
This month, the Multiple Myeloma Hub has been exploring the theme of high-risk multiple myeloma (MM). Treatment of patients with high-risk MM is the focus of this final article, in...
Subscribe to get the best content related to multiple myeloma delivered to your inbox